The efficacy of GLP-1 RAs and DPP-4 inhibitors in normalizing glucose metabolism indicates the possibility of GLP-1 and GIP deficiencies under conditions of obesity and/or glucose intolerance. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.